mineralocorticoid receptor antagonists, and betablockers) is a cornerstone of modern heart failure therapy. Nevertheless, morbidity and mortality from heart failure remain high and there is a vital need for new therapies. Since the use of RAAS inhibitors may be limited by renal dysfunction, which is common in advanced heart failure, therapies that improve both cardiac and renal status are especially desirable.
In this issue of JACC: Basic to Translational Science, Science author instructions page. This study highlights the potential of gasotransmitters with primarily vasoreactive properties The inset (box) shows pathways for endogenous production of hydrogen sulphide (H 2 S). CBS ¼ cystathionine b-synthase (CBS); CSE ¼ cystathionine g-lyase; MST ¼ mercaptopyruvate sulfurtransferase. However, there remain significant limitations in extrapolating these data to the clinical setting.
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TAC-induced heart failure is an imperfect model in many ways, and even 18 weeks of follow-up may be too short in comparison to human heart failure. 
